NES-ZIONA, Israel, Dec. 10, 2012 /PRNewswire/ -- PROLOR
Biotech, Inc. (NYSE MKT:PBTH) today announced that company
management will give a corporate presentation at the Oppenheimer
23rd Annual Healthcare Conference on December 12, 2012 at 9:25 am EST. The
conference is being held December 12-13,
2012 at the Waldorf Astoria Hotel in New York City.
A live webcast of the company's presentation will be available
at
http://www.veracast.com/webcasts/opco/healthcare2012/14104417.cfm.
An archived version of the webcast will be available for 90 days
beginning about three hours after the live presentation.
For more information about the Oppenheimer 23rd
Annual Healthcare Conference, visit
http://www.opco.com/Conferences/healthcare12/index.html.
ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage
biopharmaceutical company applying unique technologies, including
patented CTP technology and its long-acting reversible-pegylation
technology, primarily to develop longer-acting proprietary versions
of already approved therapeutic proteins that currently generate
billions of dollars in annual global sales. The CTP
technology is applicable to virtually all proteins. PROLOR is
developing a long-acting version of human growth hormone, which
successfully completed a Phase II clinical trial. It also is
developing long-acting versions of Factor VIIa and Factor IX for
hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for
diabetes and obesity, all of which are in preclinical
development. For more information, visit
www.prolor-biotech.com.
PROLOR
CONTACT:
|
MEDIA
CONTACT:
|
Shai
Novik, President
|
Barbara
Lindheim
|
PROLOR
Biotech, Inc.
|
BLL
Partners, LLC
|
Tel: +1
866 644-7811
|
+1 212
584-2276
|
Email:
shai@prolor-biotech.com
|
blindheim@bllbiopartners.com
|
SOURCE PROLOR Biotech, Inc.